EGFR and bladder transitional cell carcinoma: This shows that immunotherapies (anti-PD1/PD-L1 therapies), neoadjuvant chemotherapy, radiotherapy and ERBB therapy can be used, either alone or in combination, to treat BLCA with high PMEPA1 expression.